OBJECTIVE: To investigate cyclooxygenase-2 (COX-2) mRNA expression in curatively resected non-small cell lung cancer (NSCLC) and to determine its association with prognosis. SUMMARY BACKGROUND DATA: Lung cancer is one of the most common malignancies in the world. Despite improvements in the diagnosis and treatment of NSCLC, the 5-year survival rate remains less than 15%. Identification of prognostic predictors based on molecular alterations could lead to additional diagnostic tools and eventually to more effective therapeutic options. Overexpression of COX-2 has been reported in several human malignancies, including lung cancer, but the prognostic importance of this overexpression has not been elucidated. METHODS: COX-2 mRNA expression was analyzed using a quantitative real-time polymerase chain reaction (Taqman) method in surgically resected tumor specimens from 89 patients with curatively resected NSCLC. RESULTS: COX-2 mRNA was detectable in all 89 (100%) tumor tissues. High COX-2 expression in tumors was significantly associated with inferior survival. Multivariate analysis showed that high COX-2 expression is an independent predictor of worse survival in patients with NSCLC. CONCLUSIONS: High COX-2 mRNA expression is an important biomarker for biologically aggressive disease in NSCLC and might be helpful in identifying patients who would benefit from additional therapies for controlling their disease.
OBJECTIVE: To investigate cyclooxygenase-2 (COX-2) mRNA expression in curatively resected non-small cell lung cancer (NSCLC) and to determine its association with prognosis. SUMMARY BACKGROUND DATA: Lung cancer is one of the most common malignancies in the world. Despite improvements in the diagnosis and treatment of NSCLC, the 5-year survival rate remains less than 15%. Identification of prognostic predictors based on molecular alterations could lead to additional diagnostic tools and eventually to more effective therapeutic options. Overexpression of COX-2 has been reported in several humanmalignancies, including lung cancer, but the prognostic importance of this overexpression has not been elucidated. METHODS:COX-2 mRNA expression was analyzed using a quantitative real-time polymerase chain reaction (Taqman) method in surgically resected tumor specimens from 89 patients with curatively resected NSCLC. RESULTS:COX-2 mRNA was detectable in all 89 (100%) tumor tissues. High COX-2 expression in tumors was significantly associated with inferior survival. Multivariate analysis showed that high COX-2 expression is an independent predictor of worse survival in patients with NSCLC. CONCLUSIONS: High COX-2 mRNA expression is an important biomarker for biologically aggressive disease in NSCLC and might be helpful in identifying patients who would benefit from additional therapies for controlling their disease.
Authors: R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg Journal: J Gastrointest Surg Date: 2000 Mar-Apr Impact factor: 3.452
Authors: H Achiwa; Y Yatabe; T Hida; T Kuroishi; K Kozaki; S Nakamura; M Ogawa; T Sugiura; T Mitsudomi; T Takahashi Journal: Clin Cancer Res Date: 1999-05 Impact factor: 12.531
Authors: T Hida; Y Yatabe; H Achiwa; H Muramatsu; K Kozaki; S Nakamura; M Ogawa; T Mitsudomi; T Sugiura; T Takahashi Journal: Cancer Res Date: 1998-09-01 Impact factor: 12.701
Authors: T Hida; K Kozaki; H Muramatsu; A Masuda; S Shimizu; T Mitsudomi; T Sugiura; M Ogawa; T Takahashi Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: T Hida; J Leyton; A N Makheja; P Ben-Av; T Hla; A Martinez; J Mulshine; S Malkani; P Chung; T W Moody Journal: Anticancer Res Date: 1998 Mar-Apr Impact factor: 2.480
Authors: Imtiyaz A Bhat; Roohi Rasool; Iqbal Qasim; Khalid Z Masoodi; Shabeer A Paul; Bashir A Bhat; Farooq A Ganaie; Sheikh A Aziz; Zafar A Shah Journal: Tumour Biol Date: 2014-08-12
Authors: Tonya Walser; Xiaoyan Cui; Jane Yanagawa; Jay M Lee; Eileen Heinrich; Gina Lee; Sherven Sharma; Steven M Dubinett Journal: Proc Am Thorac Soc Date: 2008-12-01
Authors: Peter P Grimminger; Jan Stöhlmacher; Daniel Vallböhmer; Paul M Schneider; Arnulf H Hölscher; Ralf Metzger; Peter V Danenberg; Jan Brabender Journal: J Oncol Date: 2009-11-22 Impact factor: 4.375